Recurrence rate of hirsutism after 3 different antiandrogen therapies

J Am Acad Dermatol. 1999 Jul;41(1):64-8. doi: 10.1016/s0190-9622(99)70408-1.

Abstract

Background: Although antiandrogens are frequently and successfully used to treat hirsutism, little attention has been paid to optimal duration of treatment and recurrence rate after cessation of therapy.

Objective: Our purpose was to determine the recurrence rate of hirsutism after 3 different antiandrogen therapies.

Methods: Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day. Hirsutism scores according to the Ferriman-Gallwey scoring system and endocrine parameters were evaluated before, during, and 1 year after withdrawal of treatment regimens.

Results: Hirsutism scores decreased significantly and similarly in spironolactone, flutamide, and cyproterone acetate treatment groups. However, 1 year after withdrawal of treatment in all antiandrogen therapy groups, hirsutism returned.

Conclusion: Antiandrogens are effective in the treatment of hirsutism. However, cessation of antiandrogen therapy is followed by recurrence.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Contraceptives, Oral / therapeutic use
  • Cyproterone / therapeutic use
  • Female
  • Flutamide / therapeutic use
  • Hirsutism / blood
  • Hirsutism / drug therapy*
  • Humans
  • Luteinizing Hormone / blood
  • Recurrence
  • Spironolactone / therapeutic use
  • Testosterone / blood

Substances

  • Androgen Antagonists
  • Contraceptives, Oral
  • Spironolactone
  • Testosterone
  • Flutamide
  • Luteinizing Hormone
  • Cyproterone